MyNeo ImmunoEngine

Precision oncology company MyNeo has released a new version of its ImmunoEngine bioinformatics platform. The update incorporates two new machine-learning algorithms, NeoMS, a transformer-based predictor based on major histocompatibility complex (MHC) ligandomic data, and NeoIM, a random-forest classifier trained to classify short peptides as either immunogenic or nonimmunogenic. The Belgian firm specializes in identifying and validating precision cancer therapies.